There was clinical significance without statistically significant upregulation in the levels of expression of hsa-miR-611 and clinically significant downregulation in the expression of CHUK, hsa-miR (-611, and -5192) and RP4-605O3.4 in the individuals with poor glycemic control compared to individuals with good glycemic control (p = 0.040 and 0.010, respectively) suggesting possible use of these biomarkers together with HbA1c in discriminating glycemic control in T2DM patients. Here, CHUK is linked to type 2 diabetes mellitus.